]>
IRCT20180802040678N4 IRCT 2020-04-01 Tabriz University of Medical Sciences Evaluation of the effects of Losartan in patients with corona virus disease 2019 Evaluation of the effects of Losartan in patients with corona virus disease 2019 2020-03-31 anticipated 100 Complete https://irct.ir/trial/46824 interventional Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Block randomizing by computer software. 3 Corona virus disease 2019 (COVID-19). Intervention 1: Intervention group: In the case group, patients will receive 25 mg losartan tablets two times daily. Intervention 2: Intervention group: Patients will receive 5 mg amlodipine daily. Yes - There is a plan to make this available What will be shared: Information about the study is available upon approval by the University's Ethics Committee. When: Starting access 6 months after publication of data To whom: Everybody Conditions: Using is not authorized Where to obtain: Applicants must send their request to the author How to obtain: Sending the request via e-mail Comments:
public Armin Sadeghi
Golgasht Ave.
Tabriz Iran (Islamic Republic of) 5166/15731 +98 41 3335 7311 arm.sad@gmail.com Tabriz University of Medical Sciences scientific Akbar Sharifi
Golgasht Ave.
Tabriz Iran (Islamic Republic of) 5166/15731 +98 41 3336 4901 ak.sharif1349@gmail.com Tabriz University of Medical Sciences Iran (Islamic Republic of) Laboratory (RT-PCR of oropharyngeal swab) confirmed COVID-19 Stable hemodynamic condition Blood pressure ≥130/85 mmHg 18 years no limit Both Patient's critical condition Cough exacerbation after initiating Losartan Increasing blood potassium levels or high baseline potassium levels New anemia Shock or decreasing blood pressure ≤ 90/60 mmHg after Losartan initiating Angioedema Acute hepatic failure Acute renal failure Bilateral renal artery stenosis History of uncontrolled hypertension Pregnancy and lactation History of treatment with ACE inhibitors and ARB inhibitors Treatment with phenobarbital, rifampin and fluconazole B34.2 Coronavirus infection, unspecified Treatment - Drugs Treatment - Drugs Intervention group: In the case group, patients will receive 25 mg losartan tablets two times daily. Intervention group: Patients will receive 5 mg amlodipine daily. Mortality. Timepoint: 28 days. Method of measurement: Number of death. Performance of patients. Timepoint: Primary and 14 days after. Method of measurement: Sequential Organ Failure Assessment (SOFA) Respiratory Score. Length of hospitalization. Timepoint: 28 days. Method of measurement: Days between admission to discharge. Laboratory Findings. Timepoint: Primary and 14 days after. Method of measurement: Laboratory methods. Tabriz University of Medical Sciences Approved 2020-03-16 Ethics Committee of Tabriz University of Medical Sciences Golgasht Ave. Tabriz West Azarbaijan Iran (Islamic Republic of)